Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD‐mediated pyroptosis in colorectal cancer

Xin Guan, Ruiqi Liu, Bojun Wang, +13

Clinical and Translational Medicine

The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis

Wen‐Long Guan, Yue Ma, Yuehong Cui, +10

Frontiers in Oncology

Ubiquitin specific peptidase 5 enhances STAT3 signaling and promotes migration and invasion in Pancreatic Cancer

Jie Lian, Chao Liu, Xin Guan, +6

Journal of Cancer

Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial

Xu Li, Jinzhang Chen, Chang Liu, +17

BMC Medicine

Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor

Lele Chang, Qian Cheng, Yue Ma, +6

Journal of Immunotherapy

Esophageal CancerMedicineImmunologyGastroenterologyPathology +8

Evaluation of the Diagnostic Value of the Ultrasound ADNEX Model for Benign and Malignant Ovarian Tumors

Xiaoshan Peng, Yue Ma, Lingling Wang, +3

International Journal of General Medicine

Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial

Panpan Zhang, Si Shi, Jianming Xu, +27

European Journal of Cancer

Multifaceted modifications for a cell size‐based circulating tumor cell scope technique hold the prospect for large‐scale application in general populations

Leisheng Zhang, Linglin Zou, Yue Ma, +5

Cell Biology International

A phase II study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Updated efficacy and safety results.

Baocai Xing, Da Xu, Yanqiao Zhang, +1

Journal of Clinical Oncology

Metastatic HccPathologyPhase Ii StudyImmunotherapeuticsImmunotherapy +15

Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

Gang Jin, Shiwei Guo, Yanqiao Zhang, +4

Journal of Clinical Oncology

ImmunologyImmunoeditingPathologyPancreatic DuctalFirst-line Treatment +21